Roche leads Swiss Market up 0.6% to 12,333.93
The Swiss Market Index (SMI) rose 0.6% to 12,333.93 on Wednesday, driven by hopes of interest rate cuts from major central banks. Roche Holding surged nearly 6% after positive clinical trial results โฆ
The Swiss market closed on a firm note on Wednesday, rising 0.6% as optimism about imminent interest rate cuts from major central banks lifted investor sentiment.
The benchmark Swiss Market Index (SMI) ended the session up 73 points at 12,333.93, recovering from an early dip and briefly dipping again around mid-morning. The index swung between a low of 12,208.58 and a high of 12,357.61 during the day, showing resilience despite minor volatility. Traders bet on a more accommodative monetary policy from the Federal Reserve and peers, which typically supports stocks by lowering borrowing costs and encouraging risk-taking.
Stocks across the SMI showed mixed but mostly upward momentum. Roche Holding led the gains, soaring nearly 6% after the pharma giant announced positive early-stage clinical trial results for a new weight-loss pill. Swatch Group rose 2.5% on renewed optimism about global luxury demand, while Nestlรฉ edged up 1.1%. Smaller movers included SIG Group (up 0.82%) and Straumann Holding (up 0.61%), both benefiting from sector-specific tailwinds. Swisscom also posted modest gains.
Not all stocks participated in the rally. VAT Group fell 5.3%, while Logitech dropped 2.4%. Givaudan, Richemont, UBS Group, and several others slipped between 1% and 1.8%. Lonza Group, SGS, Holcim, and Swiss Re also closed weaker. Analysts attributed the divergence to company-specific news and sector rotation, but the broader market tone remained constructive amid expectations that central banks are nearing the end of their tightening cycles.
Read Full Story at Nasdaq News โ


